Bowel
Merck agrees on $2.2bn deal with Quotient Therapeutics to develop IBD treatment
Quotient’s somatic genomics platform technology will be used to develop the treatment
Abivax shares positive late-stage results for obefazimod in ulcerative colitis
Inflammatory bowel disease affects nearly one in every 100 people in the US
Bristol Myers Squibb’s Reblozyl receives EC approval in myelodysplastic syndromes
The treatment is already approved in the EU to treat anaemia in adults with beta-thalassaemia
GSK’s Omjjara recommended by NICE to treat myelofibrosis patients with anaemia
Myelofibrosis is estimated to affect over 1,900 people in England, Wales and Northern Ireland
GSK’s Omjjara approved by MHRA to treat myelofibrosis patients with anaemia
The rare blood cancer affects approximately one in every 500,000 people worldwide
GSK’s Omjjara approved by EC to treat myelofibrosis patients with anaemia
About 40% of myelofibrosis patients have moderate-to-severe anaemia at the time of diagnosis
GSK’s momelotinib recommended by CHMP to treat myelofibrosis patients with anaemia
About 40% of patients have moderate-to-severe anaemia at the time of diagnosis
GSK’s Ojjaara receives FDA approval to treat myelofibrosis patients with anaemia
Myelofibrosis is a rare blood cancer affecting approximately 25,000 patients in the US
GSK’s application for momelotinib in myelofibrosis with anaemia accepted by FDA
40% of myelofibrosis patients are already anaemic at the time of diagnosis and nearly all patients are estimated to develop anaemia eventually
Dovetail wins Communiqué Agility and Flexibility award at Communiqué 2021
This inaugural award was given to Dovetail amid fierce competition from four other agencies
Gut instincts lead Takeda to GI pipeline success
Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy
Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year
Late-stage candidate hit the mark in phase 3 study